Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 9:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–18 of 18 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Rasagiline/Placebo Clear all
Completed Phase 4 Interventional Results available

Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease

NCT01723228
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Rasagiline, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
45 Years to 80 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
40
States / cities
Birmingham, Alabama • Sun City, Arizona • Irvine, California + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 23, 2026, 9:52 AM EDT
Completed Phase 4 Interventional Results available

Rasagiline in the Treatment of Persistent Negative Symptoms of Schizophrenia

NCT00492336
View directory record Official record
Conditions
Schizophrenia
Interventions
rasagiline (Pharmacodynamics), Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 64 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
5
States / cities
Baltimore, Maryland • Catonsville, Maryland • Dundalk, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Sep 23, 2026, 9:52 AM EDT
Terminated Phase 2Phase 3 Interventional

Safety and Efficacy of Rasagiline in Restless Legs Syndrome

NCT01192503
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
rasagiline, placebo (sugar pill)
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
8
States / cities
Pinellas Park, Florida • Augusta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2013 · Synced Sep 23, 2026, 9:52 AM EDT
Completed Phase 3 Interventional

Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor Fluctuations

NCT00203034
View directory record Official record
Conditions
Parkinson's Disease
Interventions
rasagiline mesylate, 1.0 mg rasagiline mesylate, Placebo
Drug · Other
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
30 Years and older
Enrollment
472 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
4
States / cities
Chicago, Illinois • New York, New York • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2010 · Synced Sep 23, 2026, 9:52 AM EDT
Completed Phase 2 Interventional Results available

Image Parkinson's Disease Progression Study

NCT02789020
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Rasagiline, Placebo, Magnetic Resonance Imaging, functional Magnetic Resonance Imaging, Physical Function Performance Test
Drug · Other · Device
Lead sponsor
University of Florida
Other
Eligibility
40 Years to 77 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Sep 23, 2026, 9:52 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease

NCT01968460
View directory record Official record
Conditions
Parkinson's Disease
Interventions
P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),, Placebo, P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg),
Drug
Lead sponsor
Pharma Two B Ltd.
Industry
Eligibility
35 Years to 75 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
24
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Sep 23, 2026, 9:52 AM EDT
Not listed Phase 4 Interventional

A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's Patients

NCT01007630
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Rasagiline, Placebo
Drug
Lead sponsor
The Parkinson's Institute
Other
Eligibility
Up to 90 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Sunnyvale, California
Source: ClinicalTrials.gov public record
Updated Dec 1, 2013 · Synced Sep 23, 2026, 9:52 AM EDT
Completed Phase 2 Interventional

Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)

NCT00104273
View directory record Official record
Conditions
Dementia, Alzheimer's Disease
Interventions
Rasagiline
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
45 Years to 90 Years
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
31
States / cities
Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2009 · Synced Sep 23, 2026, 9:52 AM EDT
Completed Phase 4 Interventional Results available

Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease

NCT01049984
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Rasagiline, Placebo
Drug
Lead sponsor
Teva Neuroscience, Inc.
Industry
Eligibility
30 Years and older
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
58
States / cities
Phoenix, Arizona • Sun City, Arizona • Fountain Valley, California + 51 more
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Sep 23, 2026, 9:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Rasagiline

NCT01879748
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Rasagiline, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
20 Years to 50 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Sep 23, 2026, 9:52 AM EDT
Completed Phase 2 Interventional Results available

Rasagiline Rescue in Alzheimer's Disease Clinical Trial

NCT02359552
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Rasagiline, Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
50 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
3
States / cities
Las Vegas, Nevada • Cleveland, Ohio • Lakewood, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 9, 2020 · Synced Sep 23, 2026, 9:52 AM EDT
Completed Phase 2 Interventional Results available

Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)

NCT01786603
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Rasagiline, Placebo
Drug
Lead sponsor
Richard Barohn, MD
Other
Eligibility
21 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
10
States / cities
Phoenix, Arizona • Irvine, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2020 · Synced Sep 23, 2026, 9:52 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study With P2B001 in Subjects With Early Parkinson's

NCT03329508
View directory record Official record
Conditions
Parkinson Disease, Early Parkinson's Disease
Interventions
P2B001 0.6/0.75 mg, Rasagiline 0.75 mg, Pramipexole 0.6 mg, Marketed Pramipexole ER
Drug
Lead sponsor
Pharma Two B Ltd.
Industry
Eligibility
35 Years to 80 Years
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
45
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Sep 23, 2026, 9:52 AM EDT
Completed Phase 4 Interventional Results available

Rasagiline for the Symptomatic Treatment of Fatigue in Parkinson's Disease

NCT01168596
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Rasagiline, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
40 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
3
States / cities
Aurora, Colorado • Gainesville, Florida • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Sep 23, 2026, 9:52 AM EDT
Completed Phase 4 Interventional

A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic Therapy

NCT01497652
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Rasagiline/Placebo, Rasagiline
Drug
Lead sponsor
Georgetown University
Other
Eligibility
40 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 15, 2015 · Synced Sep 23, 2026, 9:52 AM EDT
Completed Phase 2 Interventional Results available

Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)

NCT00977665
View directory record Official record
Conditions
Multiple System Atrophy
Interventions
rasagiline mesylate, placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
30 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
15
States / cities
Irvine, California • La Jolla, California • Sunnyvale, California + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2015 · Synced Sep 23, 2026, 9:52 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

The Effect of Rasagiline on Cognition in Parkinson's Disease

NCT01382342
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Rasagiline, Placebo
Drug
Lead sponsor
Brown University
Other
Eligibility
40 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 4, 2015 · Synced Sep 23, 2026, 9:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Pressor Effect of Oral Tyramine During Ozanimod Treatment in Healthy Adult Participants

NCT04978298
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Placebo, Rasigiline, Phenelzine, Ozanimod
Other · Drug
Lead sponsor
Celgene
Industry
Eligibility
25 Years to 55 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Sep 23, 2026, 9:52 AM EDT